NDA for rusfertide submitted to the US Food and Drug Administration (FDA), with potential approval and launch this ...
NEW YORK, Feb. 25, 2026 (GLOBE NEWSWIRE) -- FTAI Aviation Ltd. (NASDAQ: FTAI) (the "Company" or "FTAI") today reported financial results for the fourth quarter and full year 2025. The Company's ...
DXP Enterprises, Inc. (NASDAQ: DXPE) today announced financial results for the fourth quarter and fiscal year ended December 31, 2025. The following are results for the three and twelve months ended ...
Adjusted Funds From Operations ("AFFO”)1 was $48.5 million1, or $0.22 per share in fourth quarter 2025, compared to $78.3 ...
MYR Group Inc. ('MYR” or the 'Company') (NASDAQ: MYRG), a holding company of leading specialty contractors serving the ...
Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, today reported financial results for the fourth quarter and full year ended December 31, 2025.
Q4 2025 Adjusted EBITDA was $281 million, compared to Adjusted EBITDA of $16 million in Q4 2024 -- Q4 2025 net income attributable to IEP was $1 million, compared to a net loss of $98 million in Q4 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results